Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $92.0K | $437K | $367K | $140K | $163K | $135K | $141K | $202K | $170K | $88.0K |
| Revenue growth | — | 375.0% | -16.0% | -61.9% | 16.4% | -17.2% | 4.4% | 43.3% | -15.8% | -48.2% |
| Operating income | -$13.8M | -$11.4M | -$11.5M | -$12.4M | -$15.2M | -$18.8M | -$19.9M | -$31.9M | -$19.8M | -$11.7M |
| Operating margin | -15004.3% | -2612.4% | -3132.4% | -8887.9% | -9295.7% | -13954.1% | -14129.8% | -15800.0% | -11630.6% | -13254.5% |
| Net income | -$7.50M | -$8.26M | -$9.83M | -$9.40M | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| Net margin | -8154.3% | -1889.9% | -2677.7% | -6717.1% | -8834.4% | -14168.1% | -13790.8% | -14337.6% | -10188.2% | -15861.4% |
| EPS (diluted) | -$0.34 | -$0.29 | -$9.77 | -$2.58 | -$0.45 | -$0.40 | -$0.40 | -$0.60 | -$30.92 | -$8.62 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.38M | -$7.94M | -$10.6M | -$9.07M | -$10.4M | -$14.0M | -$16.1M | -$21.3M | -$14.9M | -$11.0M |
| Capital expenditures | $160K | $20.0K | $51.0K | $68.0K | $22.0K | $41.0K | $86.0K | — | $18.0K | — |
| Free cash flow | -$7.54M | -$7.96M | -$10.7M | -$9.13M | -$10.4M | -$14.0M | -$16.2M | — | -$14.9M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.41M | $1.41M | $299K | $1.47M | $38.5M | $32.1M | $27.1M | $5.44M | $1.70M | $2.98M |
| Total assets | $18.9M | $14.2M | $13.8M | $20.8M | $64.6M | $57.7M | $40.5M | $19.4M | $8.61M | $5.78M |
| Total liabilities | — | — | — | — | — | — | $2.02M | $9.15M | $9.93M | $15.6M |
| Long-term debt | — | — | $2.32M | $2.10M | $1.88M | — | — | — | $2.81M | $927K |
| Shareholders' equity | $15.5M | $8.70M | $5.58M | $13.4M | $61.3M | $56.9M | $38.5M | $10.2M | -$1.32M | -$9.78M |
| Retained earnings | -$301M | -$309M | -$319M | -$328M | -$342M | -$361M | -$381M | -$410M | -$427M | -$441M |
| Shares (wtd avg diluted) | 24.2M | 32.9M | 1.11M | 10.4M | 42.2M | 48.0M | 48.0M | 48.6M | 560K | 1.62M |
Every figure is extracted from AIM ImmunoTech Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.